Additionally, combining the CXCL12-CXCR4 inhibitor AMD3100 with Sorafenib and PD-1 blockade has demonstrated antitumor effects in a mouse HCC model [185,186]. Here, CXCR4 is linked to hepatocellular carcinoma.